Navigation Links
Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
Date:3/11/2008

BERKELEY, Calif., March 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced that it will release fourth quarter and full year financial results for 2007 after the market closes on Thursday, March 13, 2008. Nile management will host a conference call and live webcast to discuss these financial results and provide an update on each of its development programs at 4:30 p.m. ET, 1:30 p.m. PT that afternoon.

Interested investors may participate in the conference call by dialing 877-548-7906 (domestic) or +1-719-325-4883 (international). Participants may also access both the live and archived webcast of the conference call from the homepage and the investor relations section of Nile's website at http://www.nilethera.com. The webcast will remain available on the company's website until the next quarterly conference call.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 19
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
4. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
5. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
6. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
7. ExonHit Therapeutics - 2007 Financial Results
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
10. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
11. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Mechanicsburg, PA (PRWEB) May 17, 2013 ... with ramp/soak capabilities. The 5R6-900 temperature controller has many ... can be plugged into the wall as a self-contained ... power supply. This distinctive detail makes the device unique, ... , The controller can also be used universally, which ...
(Date:5/17/2013)... N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability ,     New facility ... pressures , Syngenta unveiled its ... today at the company’s RTP Innovation Center. The first ... company researchers to simulate any agricultural climate and precisely ...
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
(Date:5/17/2013)... IAC Industries wants to share with you the ... to set up and furnish a research lab knowing that ... a year’s time. How does a company make choices in ... What is efficient and cost-effective? , The solution was ... The planners at DisperSol determined that the concept of modular ...
Breaking Biology Technology:New Temperature Control Products Announced by Oven Industries Inc. 2Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... 11, 2011 /PRNewswire-Asia/ -- Chinmax Medical Systems Inc., a ... regarding the progress of its lawsuit against Inverness Medical ... According to the Complaint, Inverness Medical Beijing ... the same to Chinmax customers during the period when ...
... SAN DIEGO, April 11, 2011 MabVax Therapeutics, Inc., ... the development of vaccine and antibody based therapies to ... announces that it has received the Phase 2 portion ... the National Cancer Institute (NCI) under the agency,s Streamlined ...
... VIGILAIR Systems, an industry leader in Ultraviolet Germicidal ... and first of its kind hospital study that demonstrated ... with the application of VIGILAIR® air cleaning technology in ... published article , Effect of enhanced ultraviolet germicidal irradiation ...
Cached Biology Technology:Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc. 2MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 2MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 3Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections 2
(Date:5/17/2013)... The iCargo project (Intelligent Cargo in Efficient and Sustainable ... thanks to an improvement in the efficiency of intermodal ... assist decision making. It comprises 29 European organisations with ... management. It has a budget totalling 17,000,000 and a ... is working to specify and develop the semantic components ...
(Date:5/17/2013)... LEMONT, Ill. An international team ... internal structure and cell movement inside a living frog ... showcases a new method to advance biological research and ... at Northwestern University and the Karlsruher Institut fr Technologie ... at the U.S. Department of Energy,s Argonne National Laboratory, ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society for Developmental Biology (SDB) 72nd Annual Meeting ... awards are meant to promote the entry of ... the mainstream of the basic science community and ... the SDB 2013 Annual Meeting. , Awards are ...
Breaking Biology News(10 mins):New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... scientists, mathematicians, and biologists from around the world have ... genetic ancestry of thousands of individuals in minutes, without ... will be published in the September 2007 edition of ... of its kind that require prior knowledge of an ...
... RESTON, Va. -- Based on the results of a ... basic molecular imaging/nuclear medicine research should be restored to ... largest society for molecular imaging and nuclear medicine professionals. ... National Institutes of Health, the 13-month, $700,000 report was ...
... Veterinary Medicine have demonstrated the potential of a new ... method employs a harmless gene therapy virus that transfers ... then passed naturally on to offspring. Ina Dobrinski, ... Transgenesis and Germ Cell Research at Penn Vet, and ...
Cached Biology News:Computer program traces ancestry using anonymous DNA samples 2SNM applauds NAS study showing need to restore federal nuclear medicine research funding 2SNM applauds NAS study showing need to restore federal nuclear medicine research funding 3Penn Veterinary Medicine report new strategy to create genetically-modified animals 2
... assay for mitochondrial membrane potential detection ... are detected by carboxyfluorescein (FAM)-labelled fluoromethylketone ... non-cytotoxic and bind covalently to the ... the same time the mitochondrial membrane ...
... cells were cultured in DMEM and harvested at ... to keep the antigens in their native forms, ... are arrayed on a 12-well (5 mm) adhesive ... to enhance cellular attachment and to minimize background ...
... CopyControl™ vector can be induced prior to ... provide the stability of single-copy BACs with ... other cloning vectors. The kits provide the ... insert size screening system) necessary to create ...
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
Biology Products: